ABEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Abeona Therapeutics Inc (ABEO) is not a strong buy for a beginner investor with a long-term focus at this time. The technical indicators are bearish, the financial performance is weak, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. A hold recommendation is more appropriate until there are clearer signs of improvement in financials, technical trends, or market sentiment.
The technical indicators for ABEO are bearish. The MACD is negative and expanding downward, the RSI is neutral at 39.738, and the moving averages (SMA_200 > SMA_20 > SMA_5) suggest a downward trend. The stock is trading below its pivot level of 5.136, with key support at 4.936 and resistance at 5.337. Overall, the price trend is weak.
Abeona Therapeutics is focused on innovative cell and gene therapies, including ZEVASKYN®, which could provide long-term growth potential. The company is also expanding its pipeline with AAV-based gene therapies for ophthalmic diseases.
Additionally, the stock has a 60% chance of declining further in the short term based on candlestick pattern analysis. No recent insider or hedge fund activity indicates a lack of confidence from key stakeholders.
In Q3 2025, revenue remained stagnant at $0, net income dropped to -$5,161,000 (-82.95% YoY), and EPS fell to -0.1 (-84.13% YoY). Gross margin was negative at -22, showing no improvement. Overall, the financials indicate significant challenges.
No recent analyst ratings or price target changes are available for ABEO. This lack of coverage may indicate limited interest or confidence from analysts.
